BioCentury | Oct 30, 2020
Finance

Oct. 29 Quick Takes: Ultragenyx, Scholar Rock, Galecto, Citrine-Bioprojet, miRagen-Viridian, Elpis, CASI-BioInvent

...round. The deal follows miRagen’s strategic review and assessment of its alternatives.Elpis closes $30M financingImmunotherapy play Elpis Biopharmaceuticals Corp....
BioCentury | Jun 8, 2018
Company News

Luye, Elpis collaborate on dual-targeting CAR Ts

...Luye Pharma Group Ltd. (HKSE:2186) and Elpis Biopharmaceuticals Corp. (Mass.) partnered to discover and develop dual-targeting CAR T...
...to develop immuno-oncology therapies, under which they have a CAR T therapy in IND-enabling studies. Elpis Biopharmaceuticals Corp....
Items per page:
1 - 2 of 2
BioCentury | Oct 30, 2020
Finance

Oct. 29 Quick Takes: Ultragenyx, Scholar Rock, Galecto, Citrine-Bioprojet, miRagen-Viridian, Elpis, CASI-BioInvent

...round. The deal follows miRagen’s strategic review and assessment of its alternatives.Elpis closes $30M financingImmunotherapy play Elpis Biopharmaceuticals Corp....
BioCentury | Jun 8, 2018
Company News

Luye, Elpis collaborate on dual-targeting CAR Ts

...Luye Pharma Group Ltd. (HKSE:2186) and Elpis Biopharmaceuticals Corp. (Mass.) partnered to discover and develop dual-targeting CAR T...
...to develop immuno-oncology therapies, under which they have a CAR T therapy in IND-enabling studies. Elpis Biopharmaceuticals Corp....
Items per page:
1 - 2 of 2